RE:RE:RE:RE:RE:RE:Analysts targetCYDY has been pushed higher by retail investors getting sucked in by the very questionable claims the company is making. But it has had some algos working it too. I think it traded 53 million shares one day recently - that certainly wasn't retail and it also was unlikely to be institutions either. THTX 's 7 million shares traded on the day of the cancer press release make it look like a second rate player vs. CYDY' s 53 million! Thanks for the comments on the recent data announcement.
jfm1330 wrote: When you look at Cytodyn, it did not go from 0.30$ to 8,77$ because of algorithms. The US market is just more reactive and speculative. Much more day trading. The amplitude of the price changes is much larger and it goes both ways. Big rise on positive news, but also huge drop on negative ones.
That being said. Did we learn something yesterday? The answer is yes. Epigenetics is a reality that is better understood with the progress of technical tools to reveal it. To see that tesamorelin is pushing gene expression in the right way is surely relevant to understand the overall effect of the drug. This data will have no direct role in the approval process, but at this point to know this biological effect at the gene level is a very positive sign and it increases the level of confidence in a positive outcome of a phase III trial with proper endpoints. So there is still a way to go before judging this opportunity, but the biological activity of tesamorelin on the liver is real.